CHOSA Oncology provides the Platin-DRP®, a gene-expression-based test that predicts whether a cancer patient is likely to benefit from platinum chemotherapy before treatment begins. By analyzing a routine biopsy, the test generates a score that helps clinicians select cisplatin or carboplatin more precisely, reducing unnecessary toxicity and lost time on ineffective therapies. Clinical data presented at ASCO and ELCC show the test can differentiate median survival by more than 11 months in advanced lung cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Platinum-based chemotherapies such as cisplatin and carboplatin remain cornerstone treatments for many solid tumors, yet patient responses vary widely due to biological differences. Treatment decisions are often made without knowing in advance who is most likely to benefit, leading many patients to receive therapies chosen for the population as a whole despite significant biological differences between individual tumors.
Solution
CHOSA Oncology offers the Platin-DRP®, a diagnostic test that analyzes gene expression from a routine tumor biopsy to generate a score estimating a patient's likelihood of benefiting from cisplatin or carboplatin. The test enables clinicians to identify patients more likely to respond while sparing those unlikely to benefit from unnecessary toxicity and lost time. By bringing tumor biology into platinum treatment decisions, Platin-DRP® supports more precise use of standard platinum regimens across different tumor types. The test is designed to integrate into routine clinical workflows, providing rapid, actionable scoring that supports objective decision-making for oncologists.
Target Audience
Primary customers are oncologists treating solid tumors including lung, breast, bladder, and endometrial cancers, as well as clinical researchers and pharmaceutical partners seeking biomarker-driven patient stratification for platinum-based regimens.
Features
- Gene-expression-based biomarker assay that generates a predictive score for platinum sensitivity from a routine biopsy
- Validated on the NanoString platform, with data presented at ASCO showing significant overall survival prediction in a Phase III lung cancer study
- Demonstrated clinical utility in advanced NSCLC, with high Platin-DRP® scores linked to median survival of 16.9 months versus 5.5 months for low scores
- Combined taxane and platinum biomarker approach showing up to 78% pathological complete response rate in breast cancer
- Compatible with standard clinical workflows, providing rapid and actionable results for treatment decisions